Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00669123 |
Recruitment Status :
Completed
First Posted : April 29, 2008
Last Update Posted : April 29, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoarthritis Psoriasis Joint Diseases Muskuloskeletal Diseases Skin Diseases | Drug: Chondroitin sulphate Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 126 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: 2 |
Drug: Placebo |
Experimental: 1
Chondroitin sulphate
|
Drug: Chondroitin sulphate
Chondroitin sulphate 800 mg/day
Other Name: Condrosan |
- Huskisson Visual Analogue Scale [ Time Frame: Monthly ]
- Psoriasis Area and Severity Index [ Time Frame: Monthly ]
- Lequesne Index [ Time Frame: Monthly ]
- Use of rescue medication [ Time Frame: Monthly ]
- SF-36 Health Questionaire [ Time Frame: 3 months ]
- Overall Lession Severity Scale [ Time Frame: Monthly ]
- Physician's Global Assessment of improvement [ Time Frame: Monthly ]
- Histological assessment of skin biopsies [ Time Frame: 3 months ]
- Dermatology Life Quality Index [ Time Frame: Monthly ]
- Tolerability [ Time Frame: Monthly ]
- Adverse events [ Time Frame: Monthly ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Primary knee OA according to ACR criteria;
- OA of radiological stages 1 to 3 according to Kellgren-Lawrence;
- VAS of pain ≥30;
- PASI ≥ 5.
Exclusion Criteria:
- Known allergy to chondroitin sulphate;
- Other bone and articular diseases such as chondrocalcinosis, Paget's disease, rheumatoid arthritis, psoriatic arthritis, acromegaly, hemochromatosis, Wilson's disease;
- Patients with skin conditions that could interfere in the clinical trial evaluation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00669123
Spain | |
Hospital del Mar | |
Barcelona, Spain, 08003 | |
Instituto Poal de Reumatología | |
Barcelona, Spain, 08022 |
Principal Investigator: | Pere Benito, MD | Hospital del Mar | |
Principal Investigator: | Montserrat Pérez, MD | Instituto Poal de Reumatología | |
Principal Investigator: | Ingrid Möller, MD | Instituto Poal de Reumatología |
Responsible Party: | Dr Josep Vergés Milano, Scientific Medical Director, Bioiberica |
ClinicalTrials.gov Identifier: | NCT00669123 |
Other Study ID Numbers: |
CS/IV/PSO/ART |
First Posted: | April 29, 2008 Key Record Dates |
Last Update Posted: | April 29, 2008 |
Last Verified: | April 2008 |
Chondroitin sulphate Knee osteoarthritis Psoriasis |
Osteoarthritis Osteoarthritis, Knee Joint Diseases Psoriasis Skin Diseases |
Arthritis Musculoskeletal Diseases Rheumatic Diseases Skin Diseases, Papulosquamous |